Elanco Animal Health Incorporated (ELAN) has a negative trailing P/E of -49.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 23.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.01%, forward earnings yield 4.28%. PEG 2.29.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -267.7 | 3.43 | 1.82 | 4.40 | - |
| 2017 | -41.3 | -0.07 | 1.65 | 4.44 | - |
| 2018 | 114.3 | -0.87 | 1.90 | 3.23 | - |
| 2019 | 160.0 | -4.48 | 1.96 | 3.54 | - |
| 2020 | -24.2 | 0.03 | 1.60 | 4.14 | - |
| 2021 | -28.6 | 1.21 | 1.84 | 2.90 | - |
| 2022 | -76.5 | 0.90 | 0.82 | 1.35 | - |
| 2023 | -6.0 | 0.00 | 1.18 | 1.66 | - |
| 2024 | 17.7 | -0.14 | 0.98 | 1.35 | - |
| 2025 | -48.4 | 0.29 | 1.72 | 2.38 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.13 | $2.91B | $-47.9M | -1.6% |
| 2017 | $-0.87 | $2.89B | $-310.7M | -10.8% |
| 2018 | $0.28 | $3.07B | $86.5M | 2.8% |
| 2019 | $0.18 | $3.07B | $67.9M | 2.2% |
| 2020 | $-1.27 | $3.27B | $-560.1M | -17.1% |
| 2021 | $-0.97 | $4.77B | $-472M | -9.9% |
| 2022 | $-0.15 | $4.42B | $-74M | -1.7% |
| 2023 | $-2.50 | $4.42B | $-1.23B | -27.9% |
| 2024 | $0.68 | $4.44B | $338M | 7.6% |
| 2025 | $-0.47 | $4.72B | $-232M | -4.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $1.03 | $1.00 – $1.10 | $5B | $4.98B – $5.02B | 11 |
| 2027 | $1.17 | $1.12 – $1.25 | $5.27B | $5.17B – $5.31B | 10 |
| 2028 | $1.33 | $0.35 – $2.31 | $5.53B | $5.53B – $5.53B | 6 |
| 2029 | $1.44 | $1.42 – $1.45 | $5.78B | $5.71B – $5.82B | 4 |
| 2030 | $1.53 | $1.50 – $1.54 | $5.99B | $5.91B – $6.02B | 2 |
